Obese Hypertension Study
Information source: Merck
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: MK0954, losartan +/- hydrochlorothiazide / Duration of Treatment - 16 weeks (Drug); Comparator: Placebo / Duration of Treatment - 16 weeks (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
This is a 16-week study to evaluate high systolic and diastolic blood pressure following
treatment in obese, hypertensive, adult patients.
Clinical Details
Official title: A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Mean trough sitting diastolic and systolic blood pressures
Secondary outcome: Mean trough sitting diastolic and systolic blood pressures
Eligibility
Minimum age: 21 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Obese male and female patients, ages 21-75 years, with high blood pressure
Exclusion Criteria:
Patients cannot have any other severe cardiac conditions
Locations and Contacts
Additional Information
Starting date: March 2006
Last updated: June 13, 2007
|
